Nevertheless, CYP3A4 inhibitors should not be given concomitantly with higher temsirolimus doses, such as those being investigated in clinical trials (e.g., 175 mg for mantle cell lymphoma). The gene discussed is CYP3A4; the disease is mantle cell lymphoma.